Amylin Watches Its R & D; Costs Continue to Rise
Monday, November 4, 2002
Amylin Watches Its R & D; Costs Continue to Rise
Neurogenetics Secures $10M In Series B Preferred Stock
BIOTECH
by Marion Webb, Senior Staff Writer
Amylin Pharmaceuticals, Inc...
Take 1 minute to subscribe and you'll get this story immediately, plus:
Already a subscriber? Sign in

- 52 weekly issues
- Subscriber-only digital content every business day, plus full access to SDBJ.com archives
- Book of Lists — the most comprehensive business resource in San Diego
- San Diego 500 — influential business leaders you need to know